Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING

Alere Acquires Epocal for USD 166 Million

By Labmedica International staff writers
Posted on 18 Feb 2013
Alere Inc. (Waltham, MA, USA) has acquired Epocal, Inc., (Ottawa, Canada) a provider of technologies that support blood gas and electrolyte testing at the point of care (POC).

In 2009, the two companies entered into an agreement for Alere to acquire all of Epocal’s issued and outstanding equity securities, contingent upon the achievement of gross margin and other financial milestones on or before October 31, 2014. The company did not disclose what those specific milestones were.

By developing new capabilities in near-patient diagnosis, monitoring, and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology, and diabetes.

Commenting on the acquisition, Alere CEO, Ron Zwanziger, stated, “Through its unique combination of novel diagnostic parameters and wireless-enabled technology, Epocal has set new standards in helping healthcare practitioners in critical settings deliver better patient outcomes, all the while establishing clinical efficiencies. These achievements are core to Alere’s broader mission of empowering individuals and their physicians with data that drive more responsive decision making and improved health outcomes, and we welcome Epocal into the Alere family.”

Related Links:

Alere
Epocal



PURITAN MEDICAL
Sekisui Diagnostics
EUROIMMUN AG
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more

Lab Tech.

view channel
Image:  The Becton Dickinson fluorescent activated cell sorter FACScan (Photo courtesy of the Albert Einstein College of Medicine).

Noninvasive Method Captures Circulating Tumor Cells

A clinically proven, noninvasive fluorescence virus-guided capture system of human colorectal circulating tumor cells (CTCs) from blood samples for genetic testing has been introduced. This noninvasive... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.